Navigating the high-value window of post-patent protection
Supplementary Protection Certificates (SPCs) are a uniquely technical and high-stakes form of intellectual property (IP). The extensive clinical trials and regulatory scrutiny required for marketing authorisation for pharmaceuticals and plant protection products can absorb a substantial portion of the 20-year patent term. By the time approval is granted, the period of effective market exclusivity may be significantly reduced, with direct consequences for commercial return.
SPCs, and equivalent patent term extension mechanisms found in jurisdictions worldwide, are designed to address this loss of usable patent life. However, their value lies as much in how they are secured and deployed as in the additional term they provide. Through our own offices and network of foreign associates, we advise clients on SPC and patent term extension strategy across multiple jurisdictions.
What an SPC actually does
An SPC doesn't extend the underlying patent, but it gives equivalent protection for the product covered by the marketing authorisation, within the limits of the patent, once the base patent expires. In practice, this means the clock effectively restarts on commercial exclusivity at the point when commercial exploitation actually became possible.
The duration
An SPC comes into force when the patent expires at the end of its 20-year term and can last up to five years. In practice, this provides a guaranteed minimum term of commercial exclusivity. For medicinal active ingredients, there's a further six-month extension available if the product has undergone appropriate paediatric testing - so the maximum effective extension is 5.5 years. Given that a blockbuster drug can generate hundreds of millions in annual revenue, every single additional day of exclusivity is valuable.
Scope of protection
The SPC protects the specific product authorised and any use of the active ingredient in an authorised pharmaceutical or plant protection product while the SPC is in force and covered by the underlying patent. This is narrower than a patent (it doesn't cover the active ingredient in all contexts, only authorised ones), but within that scope it's effectively iron-clad market exclusivity.
Strategic value
Patent terms are often largely consumed by regulatory approval timelines in pharma, so by the time a drug actually reaches patients, a company might have only 8-12 effective years of commercial patent life left. An SPC can restore up to 5.5 years of that, protecting exactly the period when the product is typically generating peak revenues (post-launch, post-pricing negotiations, established in the market). This makes SPCs among the most commercially significant IP rights a life sciences company can hold, and why SPC litigation (particularly around the "product protected by the patent" requirement) is so hotly contested, including before the UPC and, increasingly, in the UK courts as they chart their own post-Brexit path independent of the CJEU.
